

Medibio Limited – 22 April 2021

Medibio's Consumer Mental Health App Development on Track and Enters Second Test Phase

Melbourne, Australia and Minneapolis, MN – 22 April 2021: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF) has commenced the second test phase of its consumer mental health app (Consumer App or the App), which is progressing well and on track for commercial launch in October 2021.

The COVID-19 pandemic, along with its many social and economic consequences, has exacerbated mental health conditions amongst the global population. In the United States, the increased stress and anxiety has adversely impacted the mental health of an estimated fifty-three percent of adults and 71% reported that they could have used more emotional support¹. Medibio aims to address the increased demand for online mental health services, through the development of its Consumer App, which will be available on Android and iOS platforms.

The Company's pioneering work in the use of biometric data to aid in the early detection and screening of mental health conditions, together with its patented method of assessing stress by monitoring overnight heart rate², underpins the functionality of the Consumer App and provides a significant point of difference in the marketplace.

The second test phase that commenced 12th April, assesses the App's connectivity with wearable devices and the efficacy of undertaking the App's psychometric stress assessment on mobile and wearable devices.

The App will identify how stress is affecting the user, whether positively or negatively, considering the user's personality type and emotional characteristics. The biometric data collected during this test phase will further refine Medibio's algorithms that will produce a daily individual-based stress result for sleep, activity and heart rate that will contribute to an overall stress assessment. Medibio's Consumer App uses objective measurements from biometric data and a psychometric assessment (which measures stress that an individual "perceives") to provide users with a holistic understanding of their stress.

In order to associate their data to an actionable program for stress management, the App will also offer cognitive behavioral exercises, educational tools and goal setting features to help users develop solutions that work best for them. All of the recommended activities and resources are based on clinical research and validated by Medibio's clinical research partner Humanitas University in Italy and Medibio's Chief Medical Officer.

The App aims to take advantage of the market opportunity in the United States, and, in due course will be available for download in multiple regions globally through the App Store (iOS) and the Google Play Store (Android). The Company will announce further details regarding the revenue model for the App in future updates.

Medibio looks forward to providing further updates as we approach the October 2021 launch.

– ENDS –

This announcement is authorized for release to the market by the Board of Directors of Medibio Limited.

¹ <https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use/>; American Psychological Association's Stress in America report, Feb. 2021.

² U.S. Patent "Method and System for Monitoring Stress Conditions" granted 5th May 2020.

ASX Announcement



Medibio Limited – 22 April 2021

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

Samantha Eng

WE Communications

+61 432 063 216

WE-AUMedibio@we-worldwide.com